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Abstract
The innate immune system is responsible for the initial response of an organism to potentially harmful stressors, pathogens
or tissue injury, and accordingly plays an essential role in the pathogenesis of many inflammatory processes, including some
cardiovascular diseases. Toll like receptors (TLR) and nucleotide-binding oligomerization domain-like receptors (NLRs) are
pattern recognition receptors that play an important role in the induction of innate immune and inflammatory responses.
There is a line of evidence supporting that activation of TLRs contributes to the development and progression of
cardiovascular diseases but less is known regarding the role of NLRs. Here we demonstrate the presence of the NLR member
NOD1 (nucleotide-binding oligomerization domain containing 1) in the murine heart. Activation of NOD1 with the specific
agonist C12-iEDAP, but not with the inactive analogue iE-Lys, induces a time- and dose-dependent cardiac dysfunction that
occurs concomitantly with cardiac fibrosis and apoptosis. The administration of iEDAP promotes the activation of the NF-kB
and TGF-b pathways and induces apoptosis in whole hearts. At the cellular level, both native cardiomyocytes and cardiac
fibroblasts expressed NOD1. The NLR activation in cardiomyocytes was associated with NF-kB activation and induction of
apoptosis. NOD1 stimulation in fibroblasts was linked to NF-kB activation and to increased expression of pro-fibrotic
mediators. The down-regulation of NOD1 by specific siRNAs blunted the effect of iEDAP on the pro-fibrotic TGF-b pathway
and cell apoptosis. In conclusion, our report uncovers a new pro-inflammatory target that is expressed in the heart, NOD1.
The specific activation of this NLR induces cardiac dysfunction and modulates cardiac fibrosis and cardiomyocyte apoptosis,
pathological processes involved in several cardiac diseases such as heart failure.
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Introduction
The innate immune system is responsible for the initial response
of an organism to potentially harmful stressors, e.g. pathogens or
tissue injury, and accordingly plays an essential role in the
pathogenesis of many inflammatory diseases [1]. Recent studies
have established a relationship between the innate immune
response and some cardiovascular diseases [2]. Indeed, enhanced
TLR signaling [3] has been detected in various cardiac pathologies
including coronary heart disease, myocardial infarction and
diabetes [4,5,6]. To this regard, it has been suggested that TLR-
induced inflammation contributes to the development of acute
coronary syndromes in patients with coronary artery disease [7].
Moreover, increased TLR4 expression has been detected in the
hearts of patients with advanced heart failure [8,9].
Besides TLR, the innate response includes a family of
cytoplasmic receptors that recognize components of microorgan-
isms and abnormal/damaged host cells: the nucleotide-binding
oligomerization domain-like receptors (NLRs) [10]. NLRs activa-
tion promotes a cascade of molecular signaling events that
ultimately lead to inflammation and cell death [11]. In humans,
the NLR family is composed of 23 members that share a central
NACHT domain and a carboxy-terminal leucine-rich repeat
region [12]. NOD1 (nucleotide-binding oligomerization domain
containing 1) is a NLR member that contains an amino terminal
caspase recruitment domain (CARD) required for triggering
nuclear factor-kB (NF-kB) signaling. Activation of NOD1 involves
the formation of a multiprotein signaling complex that includes
RICK (RIP2) and initiates a variety of cellular responses including
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NF-kB activation, cytokine production and apoptosis induction
[13,14,15,16]. NOD1 is widely expressed in many cell types
including epithelial and dendritic cells [17,18]. To date, no data
have been published concerning the presence of NOD1 in the
heart, and the possible effects of its activation in cardiac cells. In
the present study, we identify the presence of this NLR in mouse
hearts. The specific stimulation of NOD1 with C12-iEDAP (iE)
induces cardiac dysfunction that occurs concomitantly with
cardiac fibrosis and apoptosis; however, iE-Lys, a chemically
related molecule to iE but lacking NOD1 activation capacity,
failed to exert cardiac dysfunction, pro-fibrotic or apoptotic effects.
Administration of a NOD1 agonist (iE) induces the activation of
NF-kB, TGF-b and apoptotic signaling pathways in whole hearts.
At the cellular level, both cardiomyocytes and cardiac fibroblasts
expressed NOD1. NLR activation in cardiomyocytes was associ-
ated with NF-kB pathway activation and with induction of
apoptosis, whereas in fibroblasts was linked to NF-kB pathway
activation and to increased expression of pro-fibrotic mediators.
The down-regulation of NOD1 by specific siRNAs blunted the
effect on the pro-fibrotic TGF-b pathway and cell apoptosis
induced after selective NOD1 activation. Collectively, our results
indicate that NOD1 stimulation induces cardiac dysfunction and
modulates cardiac fibrosis and cardiomyocyte apoptosis, patho-
logical processes involved in several diseases such as heart failure.
Materials and Methods
Chemicals
To selective stimulate NOD1 the agonist C12-iE-DAP (iE,
InvivoGen) was used [19,20]. Animals received i.p. 150 mg of iE,
Figure 1. Murine cardiac tissue expresses NOD1. Specific stimulation of NOD1 induces NF-kB pathway activation. (A) Histograms
show NOD1 mRNA levels in different mouse tissues. (B) NOD1 protein levels in mouse hearts were analyzed by western-blot. Animals received i.p.
150 mg of iEDAP (iE)/day, a selective agonist of NOD1, or vehicle (Veh.). After 2 weeks of treatment an up-regulation of P-RIP2/RIP2, P-IKK/IKK, P-IkBa/
IkBa protein ratio (B), higher p65 binding to kB motifs determined by ELISA (C), and NOS2 and COX2 (D) protein levels were observed in iE treated
hearts. NOS2 and COX2 protein values were normalized with GAPDH. Representative blots are shown in the left panels and right panels illustrate the
histograms representing the mean (band ratio)6SEM values vs. Veh. (100%); n = 4–6 animals. *p,0.05, ***p,0.001 vs. vehicle.
doi:10.1371/journal.pone.0045260.g001
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or vehicle (Veh.) per day for a total of 2 weeks [21,22]. iE-Lys was
used as negative control of C12-iE-DAP (InvivoGen). Staurospor-
ine was from Calbiochem (San Jose, CA).
Animal Care and Cell Isolation
The study was conducted following the guidelines of the
Spanish Animal Care and Use Committee, according to the
guidelines for ethical care of experimental animals of the
European Union (2010/63/EU). This study conforms to the
Guide for the Care and Use of Laboratory Animals published by
the U.S.National Institute of Health (NIH Publication No. 85–23,
revised 1996). All procedures were approved by the Bioethical
Committee of the Consejo Superior de Investigaciones Cientı´ficas
and Autonomous University of Madrid. Animals were injected
with buprenorfin (0.01 mg/kg, i.p.) and 30 min later, mice were
anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and
heparin. Hearts from adult mice were rapidly removed and
ventricular cardiomyocytes were isolated from C57BL/6J mice
using a standard enzymatic digestion as previously described [23].
Fibroblasts resent in the adult murine hearts were isolated from
the supernatant obtained during the cardiomyocyte isolation.
Fibroblasts were collected by centrifugation (300 g, 10 min) and
seeded in Dulbecco’s modified Eagle’s medium (DMEM, Gibco)
containing 100 U/ml penicillin, 100 mg/ml streptomycin, 15%
heat-inactivated FBS and 50 ng/ml of insulin/transferrin/seleni-
um (ITS, Sigma). Isolated fibroblasts expressed markers of
fibroblastic lineage, such as vimentin and DDR2 [24,25] and
showed negligible labeling with actin.
M-mode Echocardiography
Mouse hearts were visualized by echocardiography over time,
using a high-frequency micro-ultrasound system (Vevo 770;
VisualSonics, Toronto, Canada). During all experiments, mice
were anesthetized with 1.5% isoflurane gas, which resulted in
a heart rate of ca. 300 beats/min. Anesthetized animals were
placed on the Integrated Rail System and Mouse Handling Table
(provided by the manufacturer), which allows simultaneous
acquisition of temperature data (37uC, by using the integrated
heating pad). The chest of the mouse was carefully shaved, and
warm ultrasound transmission gel was applied to ensure optimal
image quality. Parasternal short-axis-view images of the heart were
recorded using a 30-MHz RMV scan head in a B-mode to allow
M-mode recordings by positioning the cursor in the parasternal
short-axis view perpendicular to the interventricular septum and
posterior wall of the left ventricle. From these recordings, the
following parameters were determined using the on-site software
Figure 2. Specific activation of NOD1 promotes cardiac dysfunction. (A) Ejection fraction obtained in mice treated for 2 weeks (daily) with
vehicle or the indicated concentrations of iE. (B) Ejection fraction obtained in mice treated during 3, 7 or 14 days with vehicle or 150 mg of iE. (C,D)
Representative echocardiographic images (M mode) of mouse hearts treated for two weeks with vehicle (C) or 150 mg of iE (D). End Systolic Diameter
(ESD), End Diastolic Diameter (EDD), and left ventricle Posterior Walls (PW) are indicated. *p,0.05, ***p,0.001 vs. vehicle.
doi:10.1371/journal.pone.0045260.g002
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cardiac package (VisualSonics): heart rate, left-ventricle ejection
fraction, fractional shortening, left-ventricle end-systolic diameter,
left-ventricle end-diastolic diameter, systolic volume and diastolic
volume.
RNA Isolation and RT-PCR Analysis
A total of 1 mg total RNA, extracted with TRIzol reagent
(Invitrogen) according to the manufacturer’s instructions, was
reverse transcribed using Transcriptor First Strand cDNA
Synthesis Kit for RT-PCR following the indications of the
manufacturer (Roche). Real-time PCR was conducted on a MyiQ
Real-Time PCR System (Bio-Rad) using Taqman Gene Expres-
sion Assay (Applied Biosystem). PCR thermocycling parameters
were 50uC for 2 min, 40 cycles of 95uC for 15 s, and 60uC for
1 min. NOD1 and the housekeeping 36B4 expression were
analyzed in parallel in all samples. For type I and type III
collagen, ANP and b-MHC amplification reaction using Quanti
SYBR Green RT protocol (Roche) was performed. Melting curve
data were collected to check the RT-PCR specificity. Each cDNA
was amplified in triplicate and the corresponding sample without
reverse transcriptase (no-RT sample) was included as negative
control. The expression of the chosen genes was normalized to
that of 36B4. The replicates were then averaged, and fold
induction was determined in a DDCt-based fold-change calcula-
tions.
Primers were used for type I collagen (forward primer 59-AAT
GGC ACG GCT GTG TGC GA-39, reverse primer 59- AGC
ACT CGC CCT CCC GTC TT-39), type III collagen (forward
primer 59-CTG TAA CAT GGA AAC TGG GGA AA-39,
(reverse primer 59-CCA TAG CTG AAC TGA AAA CCA CC-
39), ANP (forward primer 59-ATT GAC AGG ATT GGA GCC
CAG AGT-39, reverse primer 59-TGA CAC ACC ACA AGG
GCT TAG GAT-39), b-MHC (forward primer 59-TCT ACA
GGC CTG GGC TTA CCT CTC T-39, (reverse primer 59-ACT
TCC GCA GGA AGG GGG CT-39), and 36B4 was used as
a house-keeping gene to normalize relative mRNA target levels
(forward primer 59-AGA TGC AGC AGA TCC GCA T-39),
(reverse primer 59-GTT CTT GCC CAT CAG CAC C-39).
Preparation of Total Protein Cell Extracts
Tissues/cells were homogenized using a hand-held blender in
a lysis buffer (in mM: 50 Tris, 320 sucrose and 1 DTT, pH 7.0,
plus a complete protease and phosphatase inhibitor solutions,
Sigma). The homogenate was spun at 13000 g for 10 min at 4uC
and supernatants were frozen and stored at 280uC for Western
blot analysis. Protein concentrations were determined by the
Bradford assay (Bio-Rad).
Preparation of Nuclear and Cytosolic Protein Extracts
Cardiac tissue was homogenized by 10 s sonication at 4uC in
homogenization cytosolic buffer (in mM: 10 HEPES; pH 8.0,
10 KCl, 1 EDTA, 1 EGTA and 0.5% NP-40). Tissue pieces were
vortexed and centrifuged at 12000 g for 30 min. The supernatant
was the cytosolic fraction. The pellet was resuspended in 50 ml of
ice-cold nuclear buffer (in mM: 20 HEPES; pH 8.0, 0.4 NaCl, 1
EDTA, 1 EGTA and 20% glycerol) and vortexed at 4uC for
30 min. After centrifugation (12000 g at 4uC for 20 min), the
supernatant (nuclear fraction) was collected. All buffers contained
a protease and phosphatase inhibitor cocktail (Sigma).
Western Blot Analysis
Equal amounts of protein (20–80 mg) were loaded onto a 10–
12% SDS-PAGE gel. Proteins were size fractionated, transferred
to a Hybond-P membrane (GE Healthcare) and, after blocking
with 5% nonfat dry milk, incubated with the corresponding
antibodies. The blots were developed by the ECL protocol (GE
Healthcare) and different exposure times were performed for each
blot with a charge-coupled device camera in a luminescent image
analyzer (Molecular Imager, Bio-Rad) to ensure the linearity of the
band intensities. Values of densitometry were determined using
Quantity One software (Bio-Rad). Antibodies for NOD1, P-RIP2,
RIP2, P-IKK, IKK, P-IkBa, IkBa, NOS2, COX2, TRb1, TRb2,
P-Smad (Smad 2/3), Smad, PAI-1, Bcl-xL, Bax, Bad, X-IAP and
FGF-2 were from Santa Cruz Biotech or Cell Signaling
Technology.
Immunofluorescence Staining
Fibroblasts were seeded onto sterile 8-well chamber slides
(Falcon) and fixed with 2% paraformaldehyde for 10 min. Cells
were then permeabilized in ice-cold methanol and incubated with
3% BSA for 30 min. After incubating with a rabbit Ab against
NOD1 (1:200), vimentin (1:200), DDR2 (1:200) and a-actin
(1:200) (Santa Cruz Biotech. and Invitrogen Corp.) at 4uC over-
night, cells were washed with PBS followed by incubation with
Alexa 488 anti-rabbit or anti-goat secondary Abs for 1 h at RT
(1:250–1:500; Molecular Probes). For nuclear counterstaining
49,69-diamidino-29-phenylindoladihydrochloride (DAPI) was used
and this was added to the secondary Ab solution in a final
concentration of 1 mg/ml. Coverslips were mounted in Prolong
Gold antifade reagent (Molecular Probes) and examined using
a Leica TCS SP5 spectral confocal microscope. Fluorescence
intensity measurements were performed using Image J software
(NIH, Bethesda, MD, USA).
H9c2 and NIH 3T3 Cells
H9c2 (rat cardiac myocyte) and NIH 3T3 (mouse embryonic
fibroblast, MEF) cell lines were purchased from the American
Type Culture Collection, Rockville. The cell pellets were
Table 1. Cardiac parameters collected after M-mode
ultrasound evaluation of mice.
Parameter Treatment
Veh. iE 50 iE 150 iE 200 iE-Lys
BW (g) 28.960.7 28.960.8 27.760.3 28.560.6 26.560.8
HW (mg) 222.6610.9 226.7628.4 223.8616.6 233.5620.5 197.0626.0
HR (bpm) 442.868.7 460.861.3 437.8616.8 409.664.7* 437.264.5
EF (%) 74.661.1 55.461.7* 44.460.4*** 44.460.9*** 69.269.6
FS (%) 38.061.5 28.360.9*** 22.160.9*** 25.562.7*** 39.167.6
LVESD
(mm)
2.260.1 2.360.2 2.860.1 2.860.3 2.360.5
LVEDD
(mm)
3.860.1 3.860.1 3.860.1 3.960.3 3.860.4
SV (mL) 16.460.9 18.461.5 22.861.9*** 28.462.4*** 20.1610.6
DV (mL) 60.364.2 63.662.1 60.962.9 64.8612.7 62.3615.3
N 6 4 4 6 3
Data are means 6 SE. HW, heart weight, BW, body weight, HR heart rate, EF,
left-ventricle ejection fraction, FS, fractional shortening, LVESD, left-ventricle
end-systolic diameter; LVEDD, left-ventricle end-diastolic diameter; SV, systolic
volume; DV, diastolic volume;
**p,0.01,
***p,0.001 Vehicle (Veh.) vs. iE (50, 150 or 200 mg iEDAP treated mice for two
weeks).
doi:10.1371/journal.pone.0045260.t001
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resuspended in Dulbecco’s medium, supplemented with 10% FBS
and antibiotics (penicillin, 100 U/ml; streptomycin, 100 mg/ml).
MEFs from IKKb deficient mice were prepared as described in
Methods S1.
NOD1 siRNA Assays
A pool of 3 target-specific siRNAs or the equivalent scrambled
sequences was used to knockdown NOD1 gene expression (Santa
Cruz Biotech.). H9c2 and NIH-3T3 cells were transfected with
50 nM of siRNA with Lipofectamine 2000 (Invitrogen) and
stimulated with 20 mg/ml of iE. The degree of NOD1 knockdown
after 24/48 h of transfection was determined by fluorescein
conjugate control of siRNA (Santa Cruz Biotech) and by Western
blot analysis. The transfection efficiency of siRNA was 70–80%.
Transfection with scrambled RNAs did not modify the NOD1
levels in vehicle and iE-treated cells.
Figure 3. NOD1 activation increases cardiac fibrosis and TGF-b pathway in hearts isolated from iE treated mice. (A) Histological
analysis of the hearts from mice treated with vehicle (Veh.), with 150 mg of iEDAP (iE) or with 150 mg of iE-Lys (NOD1 inactive analogue of iEDAP).
Representative whole-heart cross-sections are shown (magnification x20). Myocardial fibrosis was evaluated after staining with Masson’s trichrome.
(B) Histograms show the quantitative analysis of subendocardial fibrosis is shown as collagen area vs. total tissue area (100%, mean 6 SEM; n = 4
animals per condition). (C) Histograms show type I and III collagen mRNA levels in cardiac tissue from iE and Veh. treated mice. (D) TGF-b signaling
was activated in hearts from iE-treated mice. Left panel, representative blots of TRb1, TRb2, P-Smad, Smad, PAI-1 and FGF-2 of vehicle and iE treated
mouse hearts (150 mg for 2 weeks). Right panel, shows the corresponding histograms representing the mean values vs. vehicle (100%, n = 4–6
animals). GAPDH was used to normalize all the target protein levels. *p,0.05, ***p,0.001 vs. vehicle.
doi:10.1371/journal.pone.0045260.g003
Figure 4. Selective stimulation of NOD1 induces cardiac apoptosis. Animals received i.p. 150 mg/day of iEDAP (iE), 150 mg/day of iE-Lys or
vehicle for 2 weeks. (A) TUNEL staining of cells undergoing apoptosis in cardiac tissue sections from vehicle, iE or iE-Lys-treated mice. Light
transmission of the preparations indicated that apoptotic cells were predominantly cardiomyocytes. Representative images of TUNEL positive (green)
and DAPI (blue) staining (magnification x 40). The percentages of positive TUNEL cells are indicated in the images. (B) Caspase 3, Bax and X-IAP levels
determined by Western blot from hearts of vehicle and iE mice. Left panel shows the histograms representing the mean6SEM vs. vehicle (100%).
*p,0.05, ***p,0.001 vs. vehicle; n = 4–6 animals.
doi:10.1371/journal.pone.0045260.g004
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Cell Death and Viability Detection
For detection and quantification of apoptosis, a TUNEL
commercial kit (Roche) was used, following the instructions of
the manufacturer. Cell survival assay relies on the capacity of cells
to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (Calbiochem) to colored formazan in metaboli-
cally active cells. Cardiomyocytes suspended in storage solution
were incubated for 2 h with 0.5 mg/ml of MTT in the dark at
37uC, and then 100 ml of DMSO was added. Absorbance was
measured at 595 nm. All assays were performed per triplicate.
Histological Analysis
Histological examinations were performed using 3 to 7 animals
in each experimental group. Tissue samples were fixed in 10%
buffered formalin and embedded in paraffin, and 4-mm sections
cut. Hematoxylin/eosin stain was used for analysis to assess
morphological changes, and Masson’s trichrome stain was used for
detection of collagen. Using a light microscope (Olympus x20)
examinations of the slides were performed in a blinded fashion.
NF-kB Activation Analysis
For detection and quantification of NF-kB activation an ELISA
kit (Active Motif, USA) was used, following the instructions of the
manufacturer. Absorbance was measured at 450 nm. All assays
were performed in triplicate.
Statistics
Data are presented as means 6 SEM. Statistical significance
was assessed using a Students t-test or ANOVA followed by the
Bonferroni test when appropriate. Differences with values of
p,0.05 were considered statistically significant.
Results
NOD1 is Expressed in Heart and its Specific Activation
Promotes Cardiac Dysfunction
First, we analyzed NOD1expression by quantitative RT-PCR in
different murine tissues. NOD1 was expressed in mouse hearts at
similar levels to those other analyzed tissues (Fig. 1A). NOD1
protein levels in mouse hearts were determined by western-blot
(Fig. 1B). To determine whether the NOD1-pathway was
functional in the heart, mice were treated with the selective
NOD1 activator C12-iEDAP (iE) for 2 weeks, and the activation of
the NF-kB pathway was investigated. iE treatment promoted an
increase in RIP2 phosphorylation, leading to NF-kB activation
[26] as deduced by the higher ratios of P-IKK/IKK and P-IkBa/
IkBa (Fig. 1B). Also, the binding of nuclear p65 to kB motifs was
measured and hearts from iE treated mice showed a significant
increase in NF-kB activity (Fig. 1C). Interestingly, hearts isolated
from iE-treated mice showed elevated levels of NOS2 and COX2,
a response compatible with NF-kB activation (Fig. 1D). From
a functional point of view, administration of iE for 2 weeks
promoted a time dose-dependent reduction of the ejection
fraction, fractional shortening together with a higher systolic
volume compared to vehicle treated-mice (Fig. 2A–D, Table 1,
and Fig. S1). iE treatment did not affect heart weight (HW) nor
body weight (BW) of animals, indicating that this molecule did not
induce anatomic cardiac hypertrophy for the period of use
(Table 1). The fetal genes associated to cardiac hypertrophy ANP
and b-MHC were analyzed by Real–time PCR. Hearts isolated
from iE treated mice showed a significant increase in ANP
expression compared to vehicle mice-treated ones (20.4 fold
induction, p,0.01). b-MHC was not detected in hearts of iE or
vehicle treated mice. We speculated that iE mice-treatment might
induce a previous step of cardiac hypertrophy, where some fetal
genes are activated (ANP) without presenting structural changes.
Finally, we treated mice for two weeks with the inactive analogue
of iE, iE-Lys and cardiac function was evaluated. Neither cardiac
function nor heart weight (HW) or body weight (BW) of mice were
modified by iE-Lys treatment (Table 1).
NOD1 Activation Promotes Cardiac Fibrosis and
Apoptosis
It is well established that NOD1 stimulation induces NF-kB
activation in different biological systems, and this transcription
factor can bind to specific kB sites in the TGF-b promoter,
mediating the transcription of this cytokine [27], a major player in
the development of fibrosis [28]. Accordingly, we investigated
whether NOD1 stimulation induces changes in the pro-fibrotic
TGF-b pathway in whole hearts. As Fig. 3A–B shows, an
increased deposition of collagen was detected in the hearts of iE
treated animals. Moreover, type I collagen mRNA expression was
also up-regulated in hearts from iE treated-mice (Fig. 3C). No
changes were detected in the expression of type III collagen. In
addition to this, iE-Lys (the inactive analogue of iE) did not induce
cardiac fibrosis in mice treated for two weeks (Fig. 3A–B). In
agreement with these data, the TGF-b/Smad pathway was up-
regulated in cardiac tissue from iE-treated mice (2 weeks), showing
increased protein levels of TRb2, P-Smad/Smad and PAI-1–an
important target of TGF-b signaling (Fig. 3D). Moreover, the
content of the pro-fibrotic mediator fibroblast growth factor 2
(FGF-2) was also elevated in cardiac tissue of treated mice
(Fig. 3D). Different reports have demonstrated that NLR proteins
cover functions beyond those of the innate immune response,
including the regulation of cell death. In this regard, a relationship
between NOD1 engagement and caspase activation has been
established [15,29]; therefore, the ability of iE treatment to induce
cardiac apoptosis was analyzed using TUNEL assays. Our data
show a significant degree of DNA fragmentation in cardiac tissue
of iE-treated mice (Fig. 4A) while iE-Lys (negative control for iE)
treatment did not induce cardiac apoptotic events (Fig. 4A).
Moreover, the levels of pro-apoptotic mediators, such as caspase 3
and Bax were up-regulated, while the anti-apoptotic molecule X-
IAP was down-regulated in cardiac tissue from iE-treated mice
(Fig. 4B). Together, these data demonstrated that iE administra-
tion promotes both cardiac apoptosis and fibrosis and that these
changes are accompanied by heart dysfunction.
Figure 5. The NOD1 agonist iE induces NF-kB activation and apoptosis in cardiomyocytes and H9c2 cells. Effect of NOD1 ablation
with siRNAs. (A) Native murine cardiomyocytes were incubated for 15 to 60 min, or 48 h with 20 mg/ml of iE. iE treatment induces an up-regulation
of P-RIP2/RIP2, P-IKK/IKK, P-IkBa/IkBa (15–60 min) and COX2 (48 h) protein levels. (B) iE induces a decrease in cardiomyocyte viability in a dose-
response form. Cardiomyocytes incubated for 2 h with 10–30 mg/ml of iE; staurosporine (Stau, 100 ng/ml) were used as a positive control to induce
apoptosis. (C). iE treatment induces an up-regulation of caspase 3 and Bax protein levels and down-regulates the BcL-xL and X-IAP protein levels. (D)
iE or Stau administration for 24 h in H9c2 promoted a decrease in viability as determined by MTT activity. NOD1 suppression by siRNA prevented the
effect of iE on cell viability. (E) Representative blot of NOD1, caspase 3 and GAPDH obtained in vehicle and iE treated cells, NOD1 siRNAs (siNOD1) and
NOD1 siRNA+iE in H9c2 cells. All targets protein levels were normalized by GAPDH. Data are expressed in histograms representing the mean6SEM vs.
vehicle (100%); n = 3–5 samples per condition.*p,0.05, **p,0.01 and ***p,0.001 vs. vehicle.
doi:10.1371/journal.pone.0045260.g005
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Figure 6. Selective activation of NOD1 stimulates NF-kB and TGF-b pathways in cardiac fibroblasts. (A) Confocal microscopy images of
cardiac fibroblasts isolated from mouse hearts stained for NOD1. (B) Isolated murine cardiac fibroblasts were incubated for 15 to 60 min, 24 h or 48 h
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with 40 mg/ml iE. iE-treatment induces an up-regulation of P-RIP2/RIP2, P-IKK/IKK, P-IkBa/IkBa (15–60 min), NOS2 (24 h) and COX2 (48 h) protein
levels. (C) Treatment of fibroblasts with iE for 72 h promoted an increase of TRb2, P-Smad/Smad, PAI-1 and FGF-2 protein levels. GAPDH was used to
normalize all target protein levels. Data are illustrated in histograms as mean6SEM vs. vehicle (100%; n = 3–5 samples).*p,0.05, **p,0.01 and
***p,0.001 vs. vehicle.
doi:10.1371/journal.pone.0045260.g006
Figure 7. Effect of NOD1 siRNAs on TGF-b pathway. Proposed role for NOD1 activation in cardiac cells. (A) Representative blot of NOD1,
TRb2, P-Smad/Smad, PAI-1, and GAPDH levels in vehicle, iE, NOD1 siRNAs (siNOD1) and NOD1 siRNA + iE (siNOD1+iE) NIH-3T3 cells. Scrambled siRNA
sequences did not modify the basal levels after iE-treatment. (B)The selective agonist iEDAP induces NOD1 activation. Both in cardiomyocytes and
cardiac fibroblasts, NOD1 promotes the activation of the NF-kB pathway through IKK/IkBa signaling. NF-kB activation induces a proinflammatory
response, including the expression of NOS2 and COX2. Moreover, TGF-b is activated in cardiac fibroblasts resulting in PAI-1 transcriptional activation
by TRb and Smad factors. Finally, the enhancement and activation of Bax and caspases and the downregulation of X-IAP promoted by NOD1 agonist
in cardiomyocytes, contributes to elicit an apoptotic response associated with NOD1 activation. Altogether, cardiomyocyte apoptosis and the pro-
fibrotic profile observed in cardiac fibroblasts might contribute to the onset of cardiomyopathy linked to proinflammatory disease.
doi:10.1371/journal.pone.0045260.g007
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NOD1 Stimulation Induces NF-kB and Apoptotic
Pathways Activation in Isolated Adult Murine
Cardiomyocytes
To further characterize the cardiac changes induced by NOD1
activation, cardiomyocytes isolated from mouse hearts were
incubated with iE and different parameters were evaluated. As
Fig. 5A shows, NOD 1 was expressed in native cardiomyocytes
and NF-kB signaling and their target COX2 expression were
significantly higher in iE treated cardiomyocytes. iE-Lys treatment
did not induce the expression of the specific adaptor of NOD1,
RIP2, or the NF-kB target COX2 (Fig. S2A). To analyze the
possible link between NOD1 activation and cardiomyocyte
apoptosis, murine cardiac cells were incubated with iE and
a dose-dependent loss in cell viability was observed (Fig. 5B).
Incubation of cardiomyocytes with staurosporine (Stau) was used
as a positive control to induce cell death. On analysis,
cardiomyocytes incubated with iE, exhibited higher levels of the
pro-apoptotic proteins caspase 3 and Bax, as well as lower levels of
the anti-apoptotic proteins X-IAP and Bcl-xL (Fig. 5C). iE-Lys
treatment did not modify the caspase 3 and X-IAP protein
expression (Fig. S2B). Using the cardiomyocytic cell line H9c2, to
avoid the enzymatic isolation process, we demonstrated that
NOD1 activation by iE promotes a decrease in cell viability
(Fig. 5D) and in X-IAP expression and increases caspase 3 and
Bad levels (Fig. S2C) together with NF-kB activation (Fig. S2D).
By contrast, NOD1 silencing restored full viability of H9c2 cells
treated with iE (Fig. 5D) and reduced caspase 3 activation (Fig. 5E).
NOD1 Agonist iEDAP Activates NF-kB and TGF-
b Pathways in Cardiac Fibroblasts from Adult Mice
Cardiac fibroblasts constitute an important cell population in
the heart and are involved in several physiopathological processes,
including the development of fibrosis [30]. Cardiac fibroblasts
obtained from murine hearts expressed NOD1 (Fig. 6A) and
showed higher protein levels of P-RIP2/RIP2, P-IKK/IKK and
P-IkBa/IkBa, together with a significant presence of NOS2 and
COX2 upon treatment with iE (Fig. 6B). iE-Lys treatment did not
promote the expression of the specific adaptor of NOD1, RIP2, or
the NF-kB target,COX2, (Fig. S3A). As fibroblasts are the primary
source of TGF-b in the heart and might modulate the production
of extracellular matrix [31], we analyzed the TGF-b pathway in
cardiac fibroblast treated with iE. Our results show that incubation
with iE enhances TRb2, P-Smad and PAI-1 levels as well as
higher levels of the pro-fibrotic factor FGF-2 (Fig. 6C). Again, iE-
Lys treatment did not modify the expression of the TGF-b target,
PAI-1 (Fig. S3B).Taken together, these results suggest a contribu-
tion of fibroblasts to cardiac fibrosis and to the NF-kB activity
observed in hearts of iE-treated mice. To corroborate the results
obtained in native cardiac fibroblasts but avoiding the isolation
process, a set of experiments were performed in the murine
fibroblast cell line NIH 3T3. In particular, iE treatment of NIH
3T3 induced an up-regulation of NF-kB and TGF-b/Smad/PAI-
1 pathways (Fig. S3C–D). Moreover, silencing NOD1 in NIH 3T3
cells blunted the increase in TRb2 levels, Smad phosphorylation
and PAI-1 expression (Fig. 7A) confirming the ability of NOD1 to
regulate the TGF-b pathway in response to iE challenge.
Discussion
It has been well documented that innate immune and
inflammatory responses are involved in the pathophysiological
processes of myocardial diseases [2]. TLRs and NLRs are pattern
recognition receptors that play an important role in the induction
of innate immune and inflammatory responses. There is a line of
evidence supporting that activation of TLRs contributes to the
development and progression of cardiovascular diseases, i.e.
atherosclerosis, cardiac dysfunction in sepsis and congestive heart
failure [32]. Indeed, the TLR-mediated NF-kB signaling pathway
plays a critical role in the induction of innate and immune
responses and contributes to myocardial ischemia-reperfusion
damage [33,34,35,36]. With respect to NLRs, only limited studies
have shown the effect of these pattern-recognition receptors in the
cardiovascular field [37,38], [39]. NOD proteins are NLR-family
members implicated in the induction of specific inflammatory
responses [11,12]. Diseases associated with NOD1 activity are
mostly chronic inflammatory disorders, e.g., atopic eczema and
asthma, underscoring the importance of this receptor in the
regulation of the immune response [40,41], this includes NF-kB
activation, cytokine production and, interestingly the induction of
apoptosis [14,42]. In the present report we demonstrated that
NOD1 is expressed in whole murine hearts in the range found in
other main tissues. We detected a significant protein expression of
this NLR in cardiomyocytes and cardiac fibroblasts. A significant
finding of the present study is that administration for two weeks of
the NOD1 agonist induced profound cardiac dysfunction, together
with the activation of the NF-kB and TGF-b pathways and
cardiomyocyte apoptosis (see schematic diagram Fig. 7B). More-
over, specific NOD1 stimulation promotes the activation of these
pathways in the heart –in both cardiomyocytes and cardiac
fibroblasts. iE-Lys, a chemically related molecule to iE but lacking
NOD1 activation capacity, failed to exert cardiac dysfunction,
pro-fibrotic or apoptotic effects. These results supported the
specificity of iE to induce cardiac dysfunction, fibrosis and
apoptotic effects in our mice model. Our data provide evidence
of functional activation of the classical NF-kB pathway, including
phosphorylation of IKK, and the expression of target genes, such
as COX2 and NOS2. Moreover, additional experiments per-
formed in mice embryonic fibroblast (MEFs) from wild type and
IKKb-deficient embryos, demonstrated the importance of IKK
expression for the ability of iE to induce pro-inflammatory
mediators, such as NOS2 (Fig. S4 and Methods S1).
NF-kB activation induced by NOD1 is mediated by the
association of the CARD-domain of NOD1 with the correspond-
ing CARD-domain of RIP2 [29], a kinase that mediates immune
responses induced by NOD1 and 2 [43]. The relevance of the role
of RIP2 in NOD1 signaling is also supported by the analysis of
cells derived from mice deficient in RIP2 [29]. Moreover, RIP2 is
important for NOD-induced NF-kB activation as well as for
apoptotic signaling through its association with members of the
TNFR-associated family and members of the inhibitor of the IAP
family [44]. Here, we demonstrated that this kinase is activated in
whole hearts and in cardiomyocytes and fibroblasts after NOD1
stimulation with iE.
Fibrosis can alter the hearts structure and architecture with
deleterious effects on the cardiac function [45]. In this study, we
demonstrated a significant collagen deposition together with
a higher expression of type I collagen in hearts of iE treated mice
(Fig. 3), this pathological process can induce cardiac dysfunction.
TGF-b is a cytokine that has been reported to be a major
contributor to tissue fibrosis in various organs [31]. In the heart,
TGF-b stimulates the growth of fibroblasts, thus increasing
fibrosis. This mediator acts by activating the intracellular pathways
linking TGF-b signals to plasma membrane serine/threonine
kinase receptors leading in turn to the activation of cytoplasmic
effectors such as the Smad proteins. Indeed, phosphorylation of
Smad 2/3 and its subsequent translocation to the nucleus are the
critical steps in cell signaling through this pathway, leading to
collagen deposition in the extracellular matrix. In the heart,
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profibrotic effects are frequently due to TGF-b-induced fibroblast-
dependent increases in extracellular matrix gene expression
[31,46]. In whole hearts, selective NOD-1 activation increases
collagen deposition and stimulates the TGF-b/Smad/PAI-1 axis.
At the cellular level, iE also induces an up-regulation of this
pathway in isolated cardiac fibroblasts and in NIH 3T3 cells.
Moreover, we also demonstrated that the knock-down of NOD1
expression by siRNAs efficiently prevented the effects induced by
iE on the TGF-b/Smad/PAI-1 pathway. Taken together, our
results uncover a novel molecular link between the TGF-b pathway
and cardiac NOD1 activation. In agreement with these data, it has
been described that NF-kB is bound to specific kB binding sites in
the TGF-b promoter, mediating the transcription of this cytokine
[27].
Our data identify a relationship between the increase of
myocyte apoptosis and NOD1 activation, a response that is
exacerbated after iE treatment and prevented by NOD1 in-
terference. NLR proteins are involved in the regulation of cell
death, and the presence of a CARD domain in NOD1 confers to
these proteins the ability to activate the apoptotic process [29]. In
this regard, a connection between NOD1 and caspase activation
has been established [15,29]. Using TUNEL analysis, we observed
a greater degree of DNA fragmentation in iE treated cardiac tissue
and a decrease in cardiomyocyte viability. Moreover, the levels of
pro-apoptotic mediators, such as caspase 3 and Bax were
upregulated, whereas the anti-apoptotic protein X-IAP were
down-regulated in cardiac tissue and in cardiomyocytes isolated
from treated mice. Cell treatment with the specific activator of
NOD1 iE was able to induce cell death in a dose-dependent
manner and the knock-down of this NLR, by siRNAs, was able to
prevent the increase in active caspase 3 protein levels and cell
death induced by iE in H9c2 cells. Consistent with our data, Da
Silva Correia et al., demonstrated that the NOD1 peptidic ligand,
cTriDAP induces apoptosis in MCF-cells [14] and this effect
required the expression of NOD1. Some authors described that
NOD1 can interact with several pro-caspases containing CARD
or DED domains [29], pointing to that this NLR can induce NF-
kB activation independently of its ability to promote caspase 9-
induced apoptosis.
Our report uncovers a new pro-inflammatory target that is
expressed in the heart, NOD1. The specific activation of this NLR
can modulate some pathological process such as fibrosis and
apoptosis, compromising the cardiac function. All these aspects
need to be explored in depth, especially their pathophysiological
mechanisms of activation and therefore, their contribution to some
cardiac diseases with a pro-inflammatory background, such as
heart failure.
Finally, since NLRs seems to be important determinants of
human inflammatory disorders and an in-depth understanding of
their molecular mechanism of action is required for targeted
therapies to be developed. Given this, our study focused on a mice
model, shows an increase in inflammatory-mediated up-regulation
both in cardiomyocytes and cardiac fibroblasts. Therefore,
unraveling the precise contribution of molecules involved in the
expression of the inflammatory response not only in professional
immune cells, but also in specific organ cells might help to design
additional therapeutic interventions and to provide a rationale for
identification of new biomarkers for organ dysfunction and targets,
such as the NLR system at the cardiac level.
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